John Kuruvilla, MD

The expert in hematology highlighted the toxicities reported in this trial and explained the differences observed between the 2 drugs studied.

The expert in hematology discussed the next steps for the trial and what the goals are for the use of pembrolizumab in this patient population moving forward.

The study evaluated the use of pembrolizumab compared with brentuximab vedotin in patients with relapsed or refractory classic Hodgkin Lymphoma.

The expert in hematology suggested that these findings represent a clinically meaningful benefit for patients that received pembrolizumab in the study, compared to those who received brentuximab vedotin.

Results from the study indicated that pembrolizumab (Keytruda) was superior to brentuximab vedotin (Adcetris) in patients with relapsed or refractory classic Hodgkin lymphoma (R/R cHL).